Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Pfizer Inc. will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology Annual Meeting, taking place May 30 to June 3 in ...

Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion; Proposed combination enhances Pfizer’s position as a leading company in ...

Demand for Pfizer’s COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.